| 1 |
33735152 |
10.1097/MPH.0000000000002140 |
2022 |
Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort. |
BCR |
| 2 |
33769465 |
10.5858/arpa.2020-0454-OA |
2022 |
One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia. |
BCR |
| 3 |
33780164 |
10.1002/cyto.b.22002 |
2022 |
Lymphoid blasts with aberrant myeloid marker expression and BCR/ABL1: Is it mixed phenotype acute leukemia or B lymphoblastic leukemia? |
BCR |
| 4 |
34193976 |
10.1038/s41375-021-01326-x |
2022 |
Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice. |
BCR |
| 5 |
34379028 |
10.1080/10428194.2021.1961234 |
2022 |
Early prediction of stable MR<sup>4.5</sup> by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib. |
BCR |
| 6 |
34462243 |
10.1016/j.clml.2021.07.001 |
2022 |
Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors. |
BCR |
| 7 |
34486918 |
10.1080/10428194.2021.1975191 |
2022 |
Chronic myeloid leukemia with pure erythroid leukemia blast crisis. |
BCR |
| 8 |
34493150 |
10.1080/10428194.2021.1971219 |
2022 |
Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study. |
BCR |
| 9 |
34561201 |
10.1016/j.clml.2021.08.003 |
2022 |
SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. |
BCR |
| 10 |
34582325 |
10.1080/08880018.2021.1966558 |
2022 |
Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis. |
BCR |
| 11 |
34587720 |
10.3324/haematol.2021.279125 |
2022 |
Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin. |
BCR |
| 12 |
34617186 |
10.1007/s12185-021-03231-6 |
2022 |
Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. |
BCR |
| 13 |
34617433 |
10.4274/tjh.galenos.2021.2021.0326 |
2022 |
Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients |
BCR |
| 14 |
34624079 |
10.1182/blood.2021012081 |
2022 |
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. |
BCR |
| 15 |
34657128 |
10.1038/s41375-021-01448-2 |
2022 |
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. |
BCR |
| 16 |
34662891 |
10.1182/bloodadvances.2021005245 |
2022 |
VpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group. |
BCR |
| 17 |
34676543 |
10.1111/bjh.17869 |
2022 |
Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification. |
BCR |
| 18 |
34711926 |
10.1038/s41375-021-01455-3 |
2022 |
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. |
BCR |
| 19 |
34758608 |
10.3324/haematol.2021.279807 |
2022 |
Detection of <i>ABL1</i> kinase domain mutations in therapy-naïve <i>BCR-ABL1</i>-positive acute lymphoblastic leukemia. |
BCR |
| 20 |
34775888 |
10.1080/10428194.2021.2002320 |
2022 |
Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States. |
BCR |
| 21 |
34783280 |
10.1080/10428194.2021.1999439 |
2022 |
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of <i>BCR-ABL1</i>-like acute lymphoblastic leukaemia in Indian patients. |
BCR |
| 22 |
34788984 |
10.3324/haematol.2021.279177 |
2022 |
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials. |
BCR |
| 23 |
34795418 |
10.1038/s41375-021-01470-4 |
2022 |
Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. |
BCR |
| 24 |
34816424 |
10.1111/bjh.17966 |
2022 |
Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant. |
BCR |
| 25 |
34818644 |
10.1159/000519782 |
2022 |
BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy. |
BCR |
| 26 |
34854546 |
10.1002/pbc.29441 |
2022 |
Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study. |
BCR |
| 27 |
34866312 |
10.1002/pbc.29490 |
2022 |
Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. |
BCR |
| 28 |
34872441 |
10.1080/10428194.2021.2010059 |
2022 |
<i>SOCS-2</i> gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment. |
BCR |
| 29 |
34874488 |
10.1007/s11596-021-2477-0 |
2022 |
Cytogenetic Characteristics of Childhood Acute Lymphoblastic Leukemia: A Study of 1541 Chinese Patients Newly Diagnosed between 2001 and 2014. |
BCR |
| 30 |
34882582 |
10.1172/JCI153283 |
2022 |
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. |
BCR |
| 31 |
34902205 |
10.1111/cas.15239 |
2022 |
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia. |
BCR |
| 32 |
34903489 |
10.1016/j.clml.2021.11.007 |
2022 |
State-of-the-Art Review on Myelofibrosis Therapies. |
BCR |
| 33 |
34930078 |
10.1080/10428194.2021.2015590 |
2022 |
Prediction for sustained deep molecular response for treatment-free remission. |
BCR |
| 34 |
34933827 |
10.1016/j.clml.2021.11.012 |
2022 |
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program. |
BCR |
| 35 |
34952433 |
10.1016/j.ejmech.2021.114051 |
2022 |
Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK). |
BCR |
| 36 |
34987015 |
10.1016/j.clml.2021.12.007 |
2022 |
'FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leukemia Patients Treated With ATO and ATRA-Based Therapeutic Regimen: Experience From a North Indian Tertiary Care Centre'. |
BCR |
| 37 |
34991679 |
10.1186/s13045-021-01221-z |
2022 |
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. |
BCR |
| 38 |
35011712 |
10.3390/cells11010150 |
2022 |
The Molecular Subtype of Adult Acute Lymphoblastic Leukemia Samples Determines the Engraftment Site and Proliferation Kinetics in Patient-Derived Xenograft Models. |
BCR |
| 39 |
35022343 |
10.2169/internalmedicine.8392-21 |
2022 |
Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose. |
BCR |
| 40 |
35027410 |
10.1158/1078-0432.CCR-21-3959 |
2022 |
Progress in Transplants for Acute Lymphoblastic Leukemia. |
BCR |
| 41 |
35051110 |
10.3390/vetsci9010026 |
2022 |
Feline and Canine Cutaneous Lymphocytosis: Reactive Process or Indolent Neoplastic Disease? |
BCR |
| 42 |
35061886 |
10.1182/bloodadvances.2021006076 |
2022 |
SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia. |
BCR |
| 43 |
35075985 |
10.1080/10428194.2021.2018582 |
2022 |
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. |
BCR |
| 44 |
35077445 |
10.1371/journal.pone.0261469 |
2022 |
T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival. |
BCR |
| 45 |
35082399 |
10.1038/s41417-021-00415-4 |
2022 |
CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma. |
BCR |
| 46 |
35084434 |
10.1001/jamaoncol.2021.6826 |
2022 |
Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. |
BCR |
| 47 |
35119131 |
10.1002/ajh.26487 |
2022 |
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping. |
BCR |
| 48 |
35121370 |
10.1016/j.ejca.2021.12.029 |
2022 |
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. |
BCR |
| 49 |
35123463 |
10.1186/s12920-022-01169-0 |
2022 |
A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript. |
BCR |
| 50 |
35126963 |
10.1177/20406207211072839 |
2022 |
MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. |
BCR |
| 51 |
35142153 |
10.3324/haematol.2021.280433 |
2022 |
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. |
BCR |
| 52 |
35158410 |
10.1111/ejh.13755 |
2022 |
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. |
BCR |
| 53 |
35165777 |
10.1007/s00277-022-04791-1 |
2022 |
A case report of BCR-ABL1 rearrangement in de novo adult T-cell lymphoblastic leukemia/lymphoma with normal karyotype. |
BCR |
| 54 |
35171727 |
10.1080/10428194.2022.2025797 |
2022 |
MUC4 expression by immunohistochemistry is a specific marker for <i>BCR-ABL1+</i> and <i>BCR-ABL1</i>-like B-lymphoblastic leukemia. |
BCR |
| 55 |
35181934 |
10.1111/vcp.13062 |
2022 |
A challenging case of lymphoproliferative disease in a cat. |
BCR |
| 56 |
35195876 |
10.1007/s40265-022-01680-9 |
2022 |
Olverembatinib: First Approval. |
BCR |
| 57 |
35205606 |
10.3390/cancers14040860 |
2022 |
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas. |
BCR |
| 58 |
35205731 |
10.3390/cancers14040983 |
2022 |
Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. |
BCR |
| 59 |
35210562 |
10.1038/s41409-022-01618-5 |
2022 |
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study. |
BCR |
| 60 |
35218741 |
10.1016/j.bcp.2022.114977 |
2022 |
Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases. |
BCR |
| 61 |
35230873 |
10.1126/scisignal.abk3083 |
2022 |
Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells. |
BCR |
| 62 |
35255496 |
10.1182/bloodadvances.2021006147 |
2022 |
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. |
BCR |
| 63 |
35256549 |
10.5045/br.2021.2021198 |
2022 |
Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia. |
BCR |
| 64 |
35257981 |
10.1016/j.drup.2022.100822 |
2022 |
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. |
BCR |
| 65 |
35259456 |
10.1016/j.cellsig.2022.110301 |
2022 |
Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL). |
BCR |
| 66 |
35266562 |
10.1002/ajh.26523 |
2022 |
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. |
BCR |
| 67 |
35267003 |
10.1182/blood.2021014726 |
2022 |
Pseudo-Chédiak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement. |
BCR |
| 68 |
35275990 |
10.1182/blood.2021015341 |
2022 |
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia. |
BCR |
| 69 |
35290157 |
10.1080/10428194.2022.2047673 |
2022 |
Significance of <i>RUNX1</i> mutation in <i>BCR-ABL1</i> positive acute myeloid leukemia - a diagnostic dilemma in a young woman with persistent bleeding. |
BCR |
| 70 |
35295854 |
10.3389/fcell.2022.838871 |
2022 |
Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. |
BCR |
| 71 |
35296646 |
10.1038/s41419-022-04684-1 |
2022 |
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. |
BCR |
| 72 |
35306137 |
10.1016/j.cellsig.2022.110311 |
2022 |
B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. |
BCR |
| 73 |
35319509 |
10.1097/MPH.0000000000002271 |
2022 |
Pediatric Chronic Myelogenous Leukemia in T-lineage Blast Crisis: A Reminder in Relevance. |
BCR |
| 74 |
35337248 |
10.1080/10428194.2022.2056180 |
2022 |
Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients. |
BCR |
| 75 |
35344115 |
10.1007/s11033-022-07337-w |
2022 |
Identification and validation of suitable housekeeping genes for gene expression studies in BCR-ABL1 positive B-lineage acute lymphoblastic leukemia. |
BCR |
| 76 |
35349077 |
10.1007/s12185-022-03329-5 |
2022 |
Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group. |
BCR |
| 77 |
35350909 |
10.1177/10781552221090869 |
2022 |
Real-world management of targeted therapies in chronic lymphocytic leukemia. |
BCR |
| 78 |
35358441 |
10.1016/S2352-3026(22)00038-2 |
2022 |
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. |
BCR |
| 79 |
35358442 |
10.1016/S2352-3026(22)00036-9 |
2022 |
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. |
BCR |
| 80 |
35359041 |
10.3760/cma.j.cn112151-20211028-00781 |
2022 |
[Characteristics of fusion gene expression in acute lymphoblastic leukemia]. |
BCR |
| 81 |
35361036 |
10.1080/10428194.2022.2045599 |
2022 |
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. |
BCR |
| 82 |
35389507 |
10.1111/bjh.18175 |
2022 |
Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1. |
BCR |
| 83 |
35398488 |
10.1016/j.cellsig.2022.110331 |
2022 |
SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. |
BCR |
| 84 |
35398858 |
10.1097/MPH.0000000000002456 |
2022 |
Mutational Analysis of the VPREB1 Gene of Pre-BCR Complex in a Cohort of Sporadic Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia. |
BCR |
| 85 |
35411950 |
10.1002/cbf.3702 |
2022 |
USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma. |
BCR |
| 86 |
35416325 |
10.1002/hon.3004 |
2022 |
LncRNA FIRRE stimulates PTBP1-induced Smurf2 decay, stabilizes B-cell receptor, and promotes the development of diffuse large B-cell lymphoma. |
BCR |
| 87 |
35435617 |
10.1007/s11864-022-00953-5 |
2022 |
Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T. |
BCR |
| 88 |
35440579 |
10.1038/s41467-022-29835-y |
2022 |
A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. |
BCR |
| 89 |
35450208 |
10.1177/20406207221090886 |
2022 |
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. |
BCR |
| 90 |
35472072 |
10.1371/journal.ppat.1010453 |
2022 |
Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. |
BCR |
| 91 |
35478711 |
10.2147/CMAR.S353022 |
2022 |
Primary Testicular and Cutaneous Philadelphia Chromosome Positive B-Cell Lymphoblastic Lymphoma: A Rare Case and Review. |
BCR |
| 92 |
35482146 |
10.1007/s11307-022-01733-1 |
2022 |
[<sup>18</sup>F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase. |
BCR |
| 93 |
35484080 |
10.1016/j.clml.2022.03.007 |
2022 |
Clinico-hematological and Outcome Profile of Pediatric B-other-ALL and BCR::ABL1-like pre-B-ALL: An Integrated Genomic Study From North India. |
BCR |
| 94 |
35484682 |
10.3324/haematol.2021.280557 |
2022 |
Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. |
BCR |
| 95 |
35486832 |
10.1182/blood.2021013990 |
2022 |
Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. |
BCR |
| 96 |
35523687 |
10.1016/j.anpede.2021.02.016 |
2022 |
Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia. |
BCR |
| 97 |
35548364 |
10.3389/fphar.2022.834113 |
2022 |
Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. |
BCR |
| 98 |
35570070 |
10.1016/j.blre.2022.100969 |
2022 |
Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders. |
BCR |
| 99 |
35574218 |
10.18632/oncotarget.28228 |
2022 |
Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation. |
BCR |
| 100 |
35577905 |
10.1038/s41375-022-01596-z |
2022 |
Changing causes of death in persons with haematological cancers 1975-2016. |
BCR |
Datasets
Models
